Key facts
- MagCath’s last known valuation is $5.0M (Apr 2025).
- It has raised $2.6M; the latest was Later Stage VC ($1.4M) in Apr 2025.
- Notable investors include InnoFounder, Accelerace, Herax Life Science, PSV (Denmark), Technopark Luzern.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for MagCath
- ·The full record, as it builds
Funding rounds
No funding rounds for MagCath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MagCath
Developer of a non-surgical medical device designed to solve a range of female urinary continence problems. The company's device is a single-use soft silicone tube that is inserted in the urethra, where it stays all day and has an inner valve that restores control over all bladder voiding, enabling women to get access to an alternative to mesh surgery.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2013
- Employees
- 4
- Website
- obtinu.com/
- Ownership
- Privately Held (backing)
MagCath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MagCath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MagCath in its N-PORT filings yet. We sweep new filings monthly.